A method can include providing a first neural network connected to a second neural network. The first neural network can represent B+11 and the second neural network can represent electrical properties. The method can include training the first neural network and the second neural network jointly. The method can include determining, from the trained first neural network and the trained second neural network B+11, a prediction of and electrical properties at one or more predetermined locations. The method can include outputting the prediction of B+11 and EP.
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The shallow neural network with multiple recurrent and redundant loop-like wave mediated neuronal connections employs amplitude weighting factors and a phase parameter represented by non-planar connection paths. The presence of non-planarity in the connection paths allows faster and more efficient computations, reduced memory demands, and enhanced learning capabilities compared to traditional multi-layer deep AI/ML neural networks.
Methods and apparatus for dispensing droplets. In accordance with an implementation, an apparatus includes a dispenser, a liquid source, and a pressure source. The dispenser includes a tube having an outlet, a channel surrounding the tube, a flow path coupling the channel and the outlet of the tube. The liquid source to be coupled to the tube and to contain a liquid and the pressure source to be coupled to the channel. The liquid is to flow from the liquid source through the tube and the pressure source is to flow gas through the channel to cause a droplet of the liquid to be dispensed from the outlet of the tube.
Systems and methods for electrochemical hydrogen looping cells are described. Generating a pH swing can expedite carbon dioxide capture from oceanwater. Many embodiments implement electrochemical hydrogen looping cells that simultaneously produce acid via anodic hydrogen oxidation and base via cathodic hydrogen evolution to generate a pH change.
A skin-covered, linkage-driven implantable prosthesis, the prosthesis comprising a first linkage comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a first proximal bone and comprises a first hinge configured to rotate in parallel with a first proximal joint, a second linkage with a hollow center to configured to allow the first linkage to cross through and comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a second proximal bone, a second hinge attached to distal end of the first linkage and configured to imitate a second proximal joint, and a tip component configured to imitate a distal phalanx and connected to the first linkage by the second hinge and to the second linkage by a bottom hinge, wherein motion of the prosthesis is allowed through a linkage- driven mechanism.
CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DEVELOPPEMENT (France)
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (Germany)
Inventor
Sundaresan, Venkatesan
Khanday, Imtiyaz
Guiderdoni, Emmanuel
Mieulet, Delphine
Mercier, Raphaël
Abstract
Synthetic apomixis can be achieved in an F1 hybrid of rice by inducing MiMe mutations and egg cell expression of BBM1 in a single step, while simultaneously providing an increased efficiency of clonal seed production. This can be used to generate hybrid plants from crosses from distant subspecies parents that produce clonal seed, allowing for maintenance of heterosis in future generations.
The present disclosure provides compositions and methods for producing a crop plant or seeds of the crop plant that induce biofilm formation (e.g., biofilm comprising nitrogen-fixing bacteria), in which the crop plant or the seeds are treated with a compound of Table 1 (e.g., tannic acid).
Certain embodiments of the invention provide a synthetic genomic safe harbor in the genome of a cell. Certain embodiments provide a method of creating a synthetic genomic safe harbor in a genome. Certain embodiments of the invention provide a method of genome editing in a cell.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
11.
TEMPOROMANDIBULAR JOINT REPLACEMENT PROSTHESIS AND METHODS OF USE
Described herein are temporomandibular joint (TMJ) prosthesis (100) designs for use in animals, such as dogs and cats. The prosthesis designs include a cranial component (102) for attachment to a cranium, a mandibular component (108) for attachment to a mandible, and an articulation component. The articulation component includes a ball (116) and socket (124) joint that provides for relative movement between the cranial and mandibular components. Also described are methods of treating a mammal with the TMJ prosthesis designs.
Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L1 therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primate uPAR, e.g., a cynomolgus uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins and conjugates of the present disclosure to treat a condition associated with uPAR expression and/or activity are also provided. In some embodiments, the condition associated with uPAR expression and/or activity is cancer. Non-limiting examples of such cancers include those characterized by cancer cells that express uPAR on the surface thereof, cancers characterized by stromal cells in the tumor microenvironment that express uPAR on the surface thereof, and/or the like.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein is a method for evaluating infant suckling behavior, comprising: collecting suckling data from an infant using a vacuum measurement device, transmitting the collected suckling data to a processor, processing the collected suckling data by the processor using a pre-trained Machine Learning (ML) algorithm to identify one or more abnormalities in the infant's suckling behavior, wherein the ML algorithm has been trained on a set of training data comprising a plurality of dimensions associated with the training data, and wherein the identified one or more abnormalities are corresponding to one or more of the plurality of dimensions.
Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK, NFKB2, FOXP3, ARG1, CEBPDP, TNFα, ADAMTS4, PENK, FOSL1, DUSP1, ACTA1, AGT, ATF3, CDK1, CXCL8, SELP, VCAN, TFP12, or NR4A3 genes or any combination thereof, treatment of PCa with SELE agonists, TNFα antagonists, and/or immune checkpoint inhibitors (ICIs) are shown to be effective.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
17.
DIELECTRIC-ON-DIELECTRIC SELECTIVE DEPOSITION USING ANILINE PASSIVATION
A method includes forming a conductive material on a first dielectric layer, exposing the conductive material to aniline to produce a passivated surface of the conductive material, and after exposing the conductive material to aniline, forming a second dielectric layer on the first dielectric layer using a deposition process. The deposition process is a water-free and plasma-free deposition process, and the second dielectric layer does not form on the passivated surface of the conductive material.
C23C 16/04 - Coating on selected surface areas, e.g. using masks
C23C 16/52 - Controlling or regulating the coating process
C23C 16/18 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the deposition of metallic material from metallo-organic compounds
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
C23C 16/44 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition (CVD) processes characterised by the method of coating
Recovering symbols from a stripped binary includes representing the stripped binary as a plurality of graph of graphs (GoG) representations, converting the plurality of GoGs into a plurality of expressive representations of each function in the stripped binary, training a machine learning (ML) model using the expressive representations, and determining a missing symbol of at least one of the functions based on an output of the ML model. Information relating to functions is and interactions between functions are used to train an ML to determine similarity of two functions. Based on similarities, missing symbols may be inferred and used to enable updates to the stripped binary file where source code is not available.
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Germany)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Panetta, Francis Julian
Babaei, Vahid
Esfahani, Halehossadat Mohammadian
Luci, Emiliano
Prof. Seidel, Hans-Peter
Abstract
Disclosed herein is a manufacturing system (100, 300). The execution of the machine executable instructions (112) causes a computational system (104) to: receive (200) a release profile (114, 720, 722) for an object to be constructed of one or more materials; construct (202) a similarity cost function (116) dependent on a difference between a simulated release curve (118) of a trial density field (120) and the release profile for the object; construct (204) an optimization problem (122) comprising the similarity cost function and a manufacturing penalty function (124); construct (206) an optimized density field (126) by numerically solving the optimization problem to provide the trial density field that minimizes the optimization problem; and provide (210) a three-dimensional design (130, 730, 732, 734) of the object using the optimized density field that minimizes the optimization problem.
NatureNature 565: 91–95). The parthenogenesis efficiency by BABY BBOM1 itself is 10-29 %. This invention describes methods of high frequency of parthenogenesis by simultaneous expression of BABY BOOM and DWT1 transcription factors. When BABY BOOM1 and DWT1 are expressed together through egg cell-specific promoters, parthenogenesis efficiencies of up to 90 % are achieved. These high parthenogenesis efficiencies are a prerequisite for field applications of synthetic apomixis in crop plants.
This disclosure provides systems, methods, and apparatus related to high-temperature thermal energy storage. In one aspect, a composite material includes a ceramic and graphite flakes dispersed in the ceramic. The ceramic serves as a matrix of the composite material. The ceramic is an oxide, a carbide, a boride, or a nitride. The graphite flakes are about 20 weight % to 35 weight % of the composite material. The composite material has a porosity of about 5% to 40%.
C04B 35/52 - Shaped ceramic products characterised by their composition; Ceramic compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on non-oxides based on carbon, e.g. graphite
22.
CHROMIUM AND ARSENIC SEPARATIONS USING POROUS ORGANIC FRAMEWORKS
The disclosure provides for porous organic frameworks functionalized to comprise pendant amino-dial groups and/or amino-polyol groups, and uses thereof, including for use in selectively capturing and/or separating anionic contaminants, such as chromium and arsenic oxyanions, including Cr(O), Cr(ll), Cr (III), Cr (IV), and/or Cr (VI), from other components.
Methods for analyzing the metastatic potential of circulating tumor cells (CTCs). Methods including analyzing growth signaling autonomy, methods for determining the likelihood of tumor metastases, and methods of treating a cancer determined to be likely to metastasize.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
A latent heat battery (LHB) is provided that stores latent heat for on-demand use (e.g., for conversion into electricity) and that cycles through charge and discharge cycles. In the charge cycle, a phase change material or PCM (e.g., silver) residing in an inner chamber of the battery is heated to or beyond its melting temperature, thereby storing latent heat within the battery. Illustratively, the heating may occur by collecting or focusing solar energy, or by powering an internal heater (e.g., a resistance heater). In the discharge cycle, the stored latent heat is extracted as the PCM freezes, through a heat pipe or some other construct that couples the PCM to the environment external to the LHB.
basis (additionally applicable on a population level), by analyzing how the machine-learning model responds to the input query, and outputting a prediction of model generalization for the machine-learning model based on the one or more metrics.
A core-shell particle system for performing nucleic acid amplification of targets includes particles having a hydrogel outer shell surrounding a core region that is substantially devoid of hydrogel, wherein the outer shell comprises pores having a size that permit the passage of the targets and nucleic acid reagents into the core region from an external environment surrounding the particles while substantially preventing the escape of amplicons generated in the core region in response to nucleic acid amplification. The system is used by mixing the particles with target and nucleic acid amplification reagents and partitioning the particles from one another. The particles are incubated for a period of time so as to generate amplicons. The particles are then de-partitioned from one another. The de-partitioned particles are then exposed to a dye or fluorescent reporter that is specific to nucleic acids or to a target amplicon and optically interrogated.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
28.
SYSTEMS, DEVICES AND METHODS FOR SORTING MOVING PARTICLES
Systems, devices and methods for sorting particles utilizing focus stacking of two-dimensional images are described. Such systems, devices and methods may further provide for particle processing and may encompass, on a microfluidic scale, sample enrichment, sample mixing, sample/particle sorting, verification of sorting and feedback-based optical sorting.
in vivo ex vivoIn vivo In vivo imaging can include an imager and an optical front-end. Such front-ends can include a collimator and a filter. The combination can be used to reduce interference or noise coming from oblique light. Additional systems can be used for laparoscopic imaging and/or image-guided surgery, such as tumor resection.
30.
COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NF AT, NF-KB and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.
in vitroin vivoin vivoin vivoin vivo, or by administering to an individual in need thereof T cells (such as CAR T cells) genetically manipulated to have increased XCL1 polypeptide expression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
32.
PIEZOELECTRIC MICROMACHINED ULTRASONIC TRANSDUCERS FOR BLOOD PRESSURE MONITORING
Methods and compositions for rejuvenating cells are provided. In certain aspects, the method includes increasing, in the cells, the activity of one or more of the transcription factors (TFs) presented herein. In certain aspects, the method includes decreasing, in the cells, the activity of one or more of the TFs presented herein. In certain aspects, the method includes increasing activity of one or more and decreasing the activity of one or more of TFs presented herein
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
35.
SYSTEMS AND METHODS FOR CONTROLLING AND ENHANCING IMMUNE CELL SIGNALING
Systems and methods for activating immune cells are described. Immune cells can be activated using IgG bound with antigen or via light and light sensitive peptides. An immune cell can be genetically manipulated to express a light sensitive peptide. Light is illuminated on the immune cell to activate it. The light sensitive peptide includes a means for locating to the cellular membrane, an activating domain, and a clustering domain that is responsive to light. Systems and methods for controllably inducing antibody-dependent phagocytosis are also described.
344 precursor powders with lower molar percentages of NaCl resulting in a composition with reduced or no-crystallinity and an increased concentration of Na vacancies.
H01M 10/05 - Accumulators with non-aqueous electrolyte
H01M 10/056 - Accumulators with non-aqueous electrolyte characterised by the materials used as electrolytes, e.g. mixed inorganic/organic electrolytes
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
37.
MINIATURE MAGNETIC SHIELDS WITH MAGNETIC THROUGH SUBSTRATE VIAS
One or more embodiments relate to custom microfabricated magnetic shields that are configured to provide isolation of superconducting electronics (SCE) circuits/chips from each other and an external environment. Whereas most superconducting circuits require magnetic shielding and most shields work by fully encapsulating the circuits, leaving little access for quite rigid and fragile fibers, one or more embodiments allow custom magnetic shield shapes to be fabricated. The shield design can depend upon the particular application, and many variations are possible. For example, in an optical interconnect application, the design can depend on whether an active (VCSEL) or passive photonic (grating/edge coupled) scheme is selected — a flexible solution is provided that supports both techniques. The shields can be created by depositing a monolithic layer conformally in a pit that has been fabricated in a silicon substrate. In embodiments, to improve the shielding, magnetic vias composed of permalloy can be introduced into the shield design. The vias can connect the magnetic shield to a permalloy layer beneath the silicon substrate.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
39.
SYSTEMS AND METHODS FOR FULLY WIRELESS AND BATTERYLESS LOCALIZATION AND PHYSIOLOGICAL MOTION DETECTION
A battery-less, wirelessly powered localization system is described. In an embodiment, a wirelessly powered localization system, includes an external Tx antenna that generates a radio frequency (RF) signal that wirelessly powers a set of one or more localizers, an external Rx antenna that receives an output from the localizers, a localizer including: an Rx antenna that receives a radio frequency (RF) signal from an external Tx antenna, a passive four-stage full-wave CMOS rectifier that generates a DC voltage using the received RF signal, a low-dropout regulator that generates a stable DC voltage based on the rectifier-generated voltage, a frequency divider circuit to divide the frequency of received RF signal, and a Tx antenna that outputs an RF signal at the divided frequency to the external Rx antenna.
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
G01S 1/02 - Beacons or beacon systems transmitting signals having a characteristic or characteristics capable of being detected by non-directional receivers and defining directions, positions, or position lines fixed relatively to the beacon transmitters; Receivers co-operating therewith using radio waves
40.
COVALENT, CHEMOGENETIC ACTIVATORS FOR K2P POTASSIUM CHANNELS AND USES THEREOF
Disclosed herein are, inter alia, activators of K2P potassium channels and pharmaceutical compositions thereof, and methods comprising their use for the treatment of diseases or adverse conditions related to low TREK family protein activity.
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (USA)
Inventor
Mohan, Mood
Choudhary, Hemant
Pidatala, Venkataramana R.
Simmons, Blake A.
Singh, Seema
Gladden, John M.
Abstract
The present invention provides for a method to deconstruct a biomass: the method comprising: introducing a solvent comprising a Schiff-base ionic liquid (SBIL) to a biomass, such that the solvent solubilizes at least a part of the biomass to form a solubilized biomass mixture.
The present invention provides methods of treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
43.
RARE EARTH AND GROUP 4 CATALYSTS FOR AMBIENT CONVERSION OF DINITROGEN TO SECONDARY SILYLAMINES
Compositions and methods enhancing a patient's immune response to an immune stimulatory composition are disclosed. In certain embodiments, the method includes administering a composition comprising a PHD pathway inhibitor and a vaccine to a subject.
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.
Disclosed herein are DARPin backbones that form multimer and self-assembling protein cages that comprise proteins, which comprise DARPin backbones, fused to subunit proteins of the self-assembling protein cages and methods of making and using thereof.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
48.
SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
49.
FLEXIBLE DIRECTIONAL FREQUENCY MULTIPLEXING FOR MULTI-USER RF NETWORKS
An antenna device includes an antenna array having a plurality of antennas. An RF structure has a component that can vary phase response over frequency through the antenna array. A controller controls the component to create frequency-direction multi-beams from the antenna array. The antenna device can be part of an RF receiver and the RF structure can include a transmission line for each of the plurality of antennas and an RF signal connection to the transmission line for each of the plurality of antennas. The component can include a programmable delay element and a programmable phase element. The controller can set a delay of each programmable delay element and a phase each of programmable phase element in real-time to create frequency-direction multi-beams from the antenna array.
H01Q 3/36 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase by electrical means with variable phase-shifters
H01Q 3/40 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase by electrical means with phasing matrix
C07D 457/00 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid
C07D 457/02 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
C07D 457/04 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
51.
EXCITONICALLY COUPLED COACERVATES VIA LIQUID/LIQUID PHASE SEPARATION AND METHODS FOR MAKING THE SAME
A coacervate composition includes an aqueous solution of a salt and a conjugated polyelectrolyte, which includes: a conjugated polymer backbone having a plurality of monomers; ionic sidechains; and polar nonionic sidechains. Each of the ionic sidechains and each the polar nonionic sidechains extends from each monomer of the plurality of monomers in an alternating manner.
C08L 41/00 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing s; Compositions of derivatives of such polymers
52.
SYSTEMS AND METHODS FOR WIRELESSLY POWERED SOURCES WITH PROGRAMMABLE AMPLITUDE AND SPECTRUM SPREADING USING PULSE WIDTH MODULATION
Systems and methods of wirelessly powered stimulators and implantable pulse generators that can generate stimulations with programmable amplitudes and RF spectrum control in the RF domain are described. An embodiment includes an implantable pulse generator that includes: an Rx antenna configured to receive a radio frequency (RF) signal; a demodulator coupled to the Rx antenna, the rectifier, and a source, and configured to control an output of a train of mini-pulses, based on the RF signal, each mini-pulse having a voltage amplitude and a pulse width (on-portion) smaller than a pulse width TO; and stimulation circuitry 250 coupled to receive the train of minipulses and deliver the train of mini-pulse to an electrode, where the train of mini-pulses to the electrode effectively corresponds to a stimulation pulse, having a pulse width TO and an amplitude that is a function of the pulse widths of the mini-pulses.
A nanoparticle comprising a cytoplasmic type citrus leprosis virus-like particle (CiLV-C) p29 protein coat and an optional agent encapsulated with the protein coat is provided herein. The nanoparticles are useful for the delivery of the agents to cells or tissues.
222) includes providing a solution that contains a rare-earth element, and bubbling earth abundant nitrogen through the solution to produce atomic nitrogen (N).
The present disclosure relates to microorganisms useful in the biosynthesis of psicose. Also provided are methods of producing the disclosed microorganism and methods of producing psicose.
A target assembly capable of producing a neutron flux with a sufficient flux and energy distribution based on accelerator-driven thick target deuteron breakup includes a low-Z deuteron breakup target and a supporting structure in which the deuteron break-up target is located. The target may be formed, for example, from graphite, metallic beryllium, a beryllium-water combination or liquid lithium. The supporting structure may be formed from a material with a high thermal conductivity because of the high heat flux that is generated at the location of the target.
Compositions and methods for treating oxidative stress, and conditions where oxidative stress contributes to conditions such as diabetes, in a subject by administering an effective amount of cobinamide. Oxidative stress can be caused by, for example, increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the patient. Compositions and methods for treating oxidative stress that contributes to diabetes-associated conditions such as cardiac fibrosis, and to aortic aneurysm, lipid or protein oxidation, or DNA damage, in a subject by administering an effective amount of cobinamide.
The disclosure provides, in various aspects, methods of treating cancer in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of an osteoprotegerin inhibitor, wherein the osteoprotegerin inhibitor inhibits osteoprotegerin binding to TRAIL. In further aspects, the disclosure provides methods of achieving a therapeutic outcome in a subject in need of treatment, wherein the method comprises the administration to the subject of a treatment which inhibits OPG-mediated suppression of tumor immunity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are methods of treating a disease or condition by administering an engineered peptide of the present disclosure. Also disclosed herein are methods of making engineered peptides described herein.
The present disclosure relates generally to antibodies reactive with drug-peptide conjugates, as well as drug-peptide-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and drug-peptide-binding fragments. The antibodies and binding fragments are useful for diagnosis and treatment of cancers that present a neoantigen formed by binding of an inhibitor to an oncoprotein.
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 51/10 - Antibodies or immunoglobulins; Fragments thereof
inter aliainter alia, are methods of treating pain by administering compositions that include at least one purified free amino acid, at least one purified fatty acid, and a purified fatty acid amide, related compositions, and kits thereof.
Methods and systems for improving the diagnosis of rare diseases using electronic health records data include training a model to estimate the presence of a disease in a subject comprising: obtaining a plurality of health records comprising health information about individuals, modifying each health record of the plurality of health records to exclude certain health information, identifying potential indicators of a disease based on publicly available databases, where the disease is a rare disease (e.g., a disease that occurs in approximately one in 100,000 individuals), and the potential indicators comprise health information present in the health records and training the machine learning model using the plurality of health records and based at least in part on the results of evaluating the accuracy of the machine learning model to recommend a referral for evaluating the presence of a disease in one or more subjects.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 70/60 - ICT specially adapted for the handling or processing of medical references relating to pathologies
G06F 16/2458 - Special types of queries, e.g. statistical queries, fuzzy queries or distributed queries
G06F 16/28 - Databases characterised by their database models, e.g. relational or object models
64.
SYSTEM AND METHOD FOR INDEFINITE AND BIDIRECTIONAL NEAR INFRARED NANOCRYSTAL PHOTOSWITCHING
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY (Republic of Korea)
Inventor
Chan, Emory
Abstract
A photo-switchable nanocrystal can be provided which can include solely one or more inorganic elements. Further, a method for synthesizing photo-switchable nanocrystal can be provided which can utilize solely inorganic elements. For example, the fully inorganic element(s) can comprise lanthanide ion (Ln3+)-based phosphors. Further, the nanocrystal can be photostable and/or does not photodegrade with light excitation cycles.
C01F 17/36 - Compounds containing rare earth metals and at least one element other than a rare earth metal, oxygen or hydrogen, e.g. La4S3Br6 halogen being the only anion, e.g. NaYF4
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
65.
UL141 VARIANTS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME FOR CANCER IMMUNOTHERAPY
The present disclosure provides UL141 variants with one or more mutations, pharmaceutical compositions, diagnostic compositions, and kits containing the variants, nucleic acids and expression vectors encoding the variants, cells comprising the same, and methods of using the variants, nucleic acids, expression vectors, and cells for therapeutic and diagnostic purposes.
222 sensor genes and the redundant MAP kinases MPK4/MPK12, and HT1 protein kinase, and their genes. In alternative embodiments, provided are dominant active HT1 mutants that cause a high CO2-insensitive constitutively open stomatal phenotype. In alternative embodiments, the invention provides plants, and plant tissues, having increased water use efficiency, and drought-resistant plants, plant tissues and cells; and methods for engineering of water transpiration and water use efficiency in plants, and engineering plants with increased water use efficiency and drought-resistant plants, plant tissues and cells. For plants grown in humid regions with sufficient water availability, down-regulation of the CO2 sensor proteins provides plants that show less stomatal closing in light of the atmospheric CO2 increase for enabling enhanced CO2 influx into leaves.
Compositions and methods of treatment for osteoarthritis and cartilage damage in a subject comprising administering to a subject in need thereof an effective amount of a nicotinamide-riboside (NR) and pterostilbene (PT) in a ratio of about 2:1.
A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
SAN JOSE STATE UNIVERSITY RESEARCH FOUNDATION (USA)
Inventor
Good, Nathan Michael Good
Martinez-Gomez, N. Cecilia
Skovran, Elizabeth
Abstract
A microbial platform for rare earth element bioaccumulation comprises a bacterial culture, a medium comprising methanol, inorganic phosphate, and a swarf pulp, wherein the platform is selective for bioaccumulation of a rare earth element.
A particulate matter detection device takes holographic images of flowing particulate matter concentrated by a virtual impactor, which selectively slows down and guides larger particles to fly through an imaging window. The flowing particles are illuminated by a pulsed laser diode, casting their inline holograms on a CMOS image sensor in a lens-free mobile imaging device. The illumination contains three short pulses with a negligible shift of the flowing particle within one pulse and triplicate holograms of the same particle are recorded at a single frame revealing different perspectives of each particle. A deep neural network classifies the particles based on the acquired holographic images. The device was tested using different types of pollen and achieved a blind classification accuracy of 92.91%. This mobile and cost-effective device weighs ~700 g and can be used for label- free sensing and quantification of various bio-aerosols over extended periods.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
71.
METHOD AND APPARATUS FOR PHOTO ACOUSTIC-GUIDED ULTRASOUND TREATMENT FOR PORT WINE STAINS
Port wine birthmark, also known as port wine stain (PWS) is a skin discoloration characterized by red/purple patches caused by vascular malformation. In this disclosure, we propose a photoacoustic (PA) guided US focusing methodology for PWS treatment which combines the optical contrast- based selectivity with US penetration to focus the US energy onto the vasculature. The PA signals collected by the transducers when time-reversed and transmitted converge onto the PWS, thus, minimally affecting the neighboring tissue. We performed simulations that mimic realistic transducers and medium properties for this proof of concept study demonstrating the feasibility of the proposed methodology.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
72.
SYSTEMS, DEVICES AND METHODS FOR NEUROFEEDBACK TO PROMOTE BRAIN COHERENCE
Disclosed are devices, systems and methods for acquiring, analyzing, and utilizing neurofeedback to promote brain coherence. Neurofeedback is a form of biofeedback that allows an individual to regulate his/her brain activity by providing a visual metaphor of brain function, thereby making it accessible for manipulation. In some embodiments of the present technology, a system includes a brain signal detection device wearable by a subject and a computer device including a display and a brain-computer interface (BCI) configured to monitor brain signals and display visual, auditory, and/or tactile stimuli to the subject according to a neurofeedback threshold-based protocol to deliver brain signal coherence between the left and right hemispheres of a subject's brain.
Disclosed is a magnetic prosthetic suspension system. The system includes a magnetic implant configured to be fixedly attached to bone at a target site of a subject, a socket configured to fit over the target site of the subject, and a magnet positioned on or within the socket, where the magnet is configured to generate a magnetic attractive force between the magnetic implant and the magnet that suspends the socket at the target site of the subject.
Disclosed herein are optical systems and platforms for the simultaneous assessment of one or more properties of a sample, e.g., a biomolecule-containing pharmaceutical composition, including, e.g., aggregation, phase separation, and/or viscosity, as well as methods of using the same.
Acid degradable solid lipid nanoparticles comprise PEG conjugated to cholesterol via an acid degradable linkage comprising an azide-benzaldehyde acetal.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
76.
REVERSIBLE NANOPARTICLE AGGREGATES AND METHODS FOR DETECTING PROTEASES
In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for detecting proteases including detecting proteases in a biological sample. In alternative embodiments, products of manufacture, formulations, mixtures or kits are used for stabilizing (or substantially stabilizing) nanoparticles in a reversible aggregate, and, detecting the presence of a protease in a fluid, wherein optionally the products formulations or mixtures can aggregate or assemble into nanoparticles such that the nanoparticles undergo plasmonic coupling, and the plasmonic coupling is reversible (or substantially reversible) leading to monodisperse nanoparticles when a chemical cue or signal is added.
The present invention provides for methods and compositions for recovering high concentrations of transcripts is technically challenging for bacteria colonizing within the host environments. The invention uses Pi-seq technology in a DNA-barcoded promoter library to improve the ability to quantify transcriptional activity of bacterial genes. The invention offers a rapid way to screen and identify biosensors for chemicals and physical conditions associated with host physiology.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
79.
DIGITAL FERROFLUIDIC DEVICE AND METHOD FOR MULTIPLEXED ASSAYS AND VIRAL TESTING
A ferrofluidic fluid assay device uses swarm of millimeter-sized magnets was employed as mobile robotic agents ("ferrobots") for precise and robust handling of magnetized sample droplets and high-fidelity delivery of flexible assay workflows. Within a palm-sized printed circuit board-based programmable platform a myriad of sample handling and bioanalytical operations involved in pooled testing can be performed. This automated technology was applied using the loop-mediated isothermal amplification and detection of SARS-CoV-2 virus in clinical samples, where the test results completely matched those obtained off-chip. This technology is easily manufacturable and distributable, and its adoption for viral testing could lead to a 10 to 300-fold reduction in reagent costs, and three orders of magnitude reduction in instrumentation cost. Multiplexed assays may also be performed on a single device.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
G01N 27/06 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a liquid
80.
PEPTIDE-LOADED ANTIGEN PRESENTING CELL-DERIVED EXTRACELLULAR BLEBS AS A MOLECULARLY TARGETED VACCINE
The disclosure provides for vaccine preparations compnsing isolated or purified extracellular blebs that display engineered MHC I and MHC II peptides that target specific antigen(s) or a specific epitope(s) from a pathogen, and uses thereof, including for vaccination against the pathogen and disease.
Provided herein are compositions and methods for determining telomere length. In some embodiments, methods include attaching a telomere tagging probe to a 3' end of the telomere to generate a tagged telomere sequence and use of a splint oligonucleotide comprising a nucleic acid sequence that specifically binds to at least a portion of the telomere tagging probe and to at least a portion of the telomere.
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A system, apparatus and method are provided for operating a medical instrument with an automated surgical system such that the instrument starts and stops automatically depending on its location, orientation, and/or other information. Thus, instead of requiring continual supervision by a surgeon and/or other personnel, one or more functions of the instrument can be activated, paused, reactivated, or deactivated through normal manipulation of the instrument without interrupting or impeding the work flow. A volume of operation for a medical procedure may be identified manually or automatically, based on the nature of the procedure, the part of a patient's body involved in the procedure, and/or other factors. When the automated surgical system detects entry of the instrument into the volume of operation, the instrument is automatically activated and is subsequently automatically deactivated upon departure from the volume of operation.
A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
83.
COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF CRISPR-CAS EFFECTOR POLYPEPTIDES
The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypeptide comprising (i) a viral envelope protein and (ii) a targeting polypeptide that provides for binding to a target cell. The present disclosure provides methods of using an EDV of the present disclosure for delivery of, e.g., a nucleic acid-binding effector polypeptide, to a eukaryotic cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
84.
MODIFIED DNA BINDING PROTEINS AND METHODS OF USE THEREOF
Modified DNA-binding proteins are provided. DNA binding proteins of interest include fusion proteins having a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence in a target nucleic acid, and an epigenome modifying polypeptide. Aspects of the invention also include nucleic acids having a nucleotide sequence encoding a fusion protein of the disclosure, as well as recombinant expression vectors and cells including the same. The present disclosure further provides methods of silencing a target nucleic acid in a cell and/or epigenetically modifying transcription of a target nucleic acid using the subject fusion protein.
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/04 - Centrally acting analgesics, e.g. opioids
85.
SPECULAR REFLECTION PATH GENERATION AND NEAR-REFLECTIVE DIFFRACTION IN INTERACTIVE ACOUSTICAL SIMULATIONS
Methods and systems for generating a sound. The method includes obtaining meshes representing at least one object in a frame of an environment, the environment including a source and a receiver; determining spatial continuity information and reflection normal information of the meshes; determining, based on the spatial continuity information and the reflection normal information, reflection paths between the source and the receiver involving the at least one object, each of the reflection paths having at least one reflection point associated with the at least one object; obtaining spatially sampled results by spatially sampling a space around the at least one reflection point of reflection paths using multiple distributions of rays, the spatially sampled results correlating with geometric information of the meshes; generating reflection amplitude responses for each of multiple audible frequencies in the environment based on the spatially sampled results; and producing a sound based on the reflection amplitude responses.
The present invention provides novel bioactive and biocompatible polymers derived from salicylic acid and itaconic acid. The present invention also provides hydrogels formed from these bioactive and biocompatible polymers, and methods of using such hydrogels to promote plant growth and/or to increase drought and stress tolerance.
C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereof; Derivatives thereof
87.
NEXT-GENERATION SEQUENCING PIPELINE FOR DETECTION OF ULTRASHORT SINGLE-STRANDED CELL-FREE DNA
A method of isolating ultrashort single-stranded cell-free DNA (uscfDNA) is described as well as methods of using the uscfDNA for detecting biomarkers and diagnosing diseases and disorders.
THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventor
Shipman, Seth
Lopez, Santiago C.
Abstract
Described herein are retron-related constructs, expression systems, and methods for precisely deleting, inserting and/or replacing genomic DNA within cells. The inventors have found that CRISPR "single-cutter" methods are substantially less efficient at insertion/replacement of large fragments in comparison to the dual-cutter constructs, expression systems, and methods described herein.
A dynamic counterbalance system is provided. The dynamic counterbalance system can include a compound pulley system and an adjustment arm. The compound pulley system can include a frame, a spring, a variable radius pulley, a plurality of mounted pulleys, a plurality of moveable pulleys, and a plurality of lines. The adjustment arm can include a mountable support, a spool support, a spool, an arm inner support, a rod support, an extended rod, a rod end cap, a traveling pulley, a dynamic pulley, and a plurality of lines.
B66D 3/06 - Pulley blocks or like devices in which force is applied to a rope, cable or chain, which passes over one or more pulleys, e.g. to obtain mechanical advantage with more than one pulley
B66D 3/04 - Pulley blocks or like devices in which force is applied to a rope, cable or chain, which passes over one or more pulleys, e.g. to obtain mechanical advantage
A01K 15/02 - Training or exercising equipment, e.g. mazes or labyrinths for animals
A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
A63B 21/00 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
90.
FIBROBLAST ACTIVATION PROTEIN ALPHA-CLEAVABLE PRO-PEPTIDES AND METHODS OF USE
in vivoin vivo. In some embodiments, a pro-peptide of the present disclosure comprises a membrane interacting domain, a masking domain, and a FAPα cleavage site. The masking domain, when linked to the membrane interacting domain, is effective to inhibit interaction of the membrane interacting domain with a phospholipid bilayer. The FAPα cleavage site is disposed between the membrane interacting domain and the masking domain. The membrane interacting domain may be conjugated to one or more therapeutic agents, non-limiting examples of which include radioisotopes. Also provided are methods of treating a condition associated with FAPα expression in a subject in need thereof, such methods comprising administering an effective amount of a pro-peptide of the present disclosure to the subject.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
Disclosed are methods and compositions for inhibiting endocytosis and enhancing function of hematopoietic stem cells. Certain aspects are directed to increasing MYCT1 activity or expression to improve hematopoietic stem cell self-renewal and/or engraftment ability.
A surface-emitting, single mode laser includes a gain medium and a photonic structure. The gain medium is configured to emit an electromagnetic wave. The photonic structure is electromagnetically coupled to the gain medium and has a cavity mode-dependent scaling of losses so that higher order modes are coupled to more lossy bands and a fundamental mode, at a high symmetry point, is coupled to a less lossy band of the photonic structure.
93.
III-NITRIDE-BASED VERTICAL CAVITY SURFACE EMITTING LASER (VCSEL) WITH A DIELECTRIC P-SIDE LENS AND AN ACTIVATED TUNNEL JUNCTION
A III-nitride-based vertical cavity surface emitting laser (VCSEL) includes an active region between p-type and n-type layers; and a curved mirror on or above the p-type layer such that the p-type layer is between the active region and the curved mirror. The VCSEL includes a tunnel junction between the p-type layer and a curved mirror, wherein the tunnel junction is a planar tunnel junction and a p++-type layer of the tunnel junction is activated through sidewalls of the VCSEL. The curved mirror is formed on or above the tunnel junction, such that the tunnel junction is between the curved mirror and the p-type layer. The VCSEL further comprises a flat distributed Bragg reflector (DBR) mirror, the curved mirror comprises a curved DBR mirror, the III-nitride active region is between the flat DBR mirror and the curved DBR mirror, and the flat DBR mirror and the curved DBR mirror define a cavity of the VCSEL.
H01S 5/18 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities
H01S 5/183 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only vertical cavities, e.g. vertical cavity surface-emitting lasers [VCSEL]
H01S 5/187 - Surface-emitting [SE] lasers, e.g. having both horizontal and vertical cavities having only horizontal cavities, e.g. horizontal cavity surface-emitting lasers [HCSEL] using Bragg reflection
H01S 5/10 - Construction or shape of the optical resonator
H01S 5/11 - Comprising a photonic bandgap structure
H01S 5/32 - Structure or shape of the active region; Materials used for the active region comprising PN junctions, e.g. hetero- or double- hetero-structures
H01S 5/34 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
94.
COMPOSITIONS AND METHODS FOR REDUCING IONIZING RADIATION-INDUCED HEMATOPOIETIC STEM CELL DAMAGE
The present disclosure provides methods for reducing ionizing radiation-induced damage of cells such as hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). The methods comprise introducing into HSCs and/or HPCs a fusion protein comprising (a) a zinc finger DNA binding polypeptide with an alpha-helix recognition domain configured to bind to a target nucleotide sequence in a target nucleic acid, and (b) an epigenome modifying polypeptide.
C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/117 - Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/04 - Centrally acting analgesics, e.g. opioids
Proper functioning of the human body relies on the organization of cells in 3D space. A cell's function and fate are determined by its biomolecule composition and 3D environment. The spatial identification of proteins, RNAs, DNAs, and other biomolecules in a tissue thus provides a powerful map to decipher how cells build tissues and become diseased. Thus, described herein are methods and compositions for assessing biomolecule identity (the present invention features methods and compositions for assessing biomolecule identity (e.g., genes (DNA, RNA), DNA and RNA modifications, proteins, protein modifications, lipids, sugars, metals), and abundance (e.g., RNA expression levels, protein translation levels) in a 3D tissue sample.
The disclosure further provides diagnostic, prognostic, and therapeutic methods, which are based, at least in part, on determination of the identity of a genotype of interest identified herein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
99.
MULTI-CHAIN SYNTHETIC RECEPTORS FOR SIMULTANEOUS LIGAND‑INDUCED TRANSCRIPTIONAL REGULATION AND MEMBRANE‑PROXIMAL SIGNAL TRANSDUCTION
The present disclosure generally relates to multi-chain chimeric polypeptides or receptors having distinct polypeptide chains that associate post-translationally to enable the simultaneous activation of the signaling domain and the release of a transcriptional regulator upon binding of a ligand. The disclosure also provides nucleic acid constructs, recombinant cells, vectors, pharmaceutical compositions, and methods of treatment including the multi-chain chimeric polypeptides of the disclosure. The disclosure further provides methods for simultaneously inducing T cell signaling and gene regulation in a T cell.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
100.
ALLEVIATING GRAFT VERSUS HOST DISEASE USING ENGINEERED INKT CELLS
We have discovered that allogeneic HSC-engineered human iNKT (3rdin vitroin vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4-CD8-/+ subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.
patents
